Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
NCT ID: NCT04284631
Last Updated: 2020-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
54 participants
OBSERVATIONAL
2012-01-01
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Expressiona and Diagnostic Potential of miRNAs in NSCLC
NCT05815407
Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms
NCT05553067
miRNAs in High Grade Serous Ovarian Cancer
NCT05146505
Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers
NCT02638402
Different Genetic Features Associated With Hepatic Carcinogenesis
NCT01247506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Serous carcinoma is the most common and aggressive type of epithelial ovarian cancer . Serous carcinomas are currently separated into two completely different subtypes either histologically or biologically, lowg rade and high grade, based on both degree of nuclear atypia and the number of mitoses.
Current therapy is based on few traditional prognostic factors, such as tumor stage and postoperative tumor residual mass. Identification of new molecular markers could help in significant modification of treatmant improving clinical prognosis The ErbB family of tyrosine kinase receptors (epidermal growth factor (EGF) receptors) plays a role in the tumorigenesis of several types of solid tumors. The abnormal activation of these receptors has been associated with various pathological processes especially cellular transformation .
EGFR is involved in various stages of cancer growth, such as tumor initiation, angiogenesis and metastasis. Also, it participates by various pathways as a proto-oncogene in several types of cancers such as gastrointestinal and breast ones. So, it is an attractive target for oncogenic therapy HER2 protooncogene is involved in the development of many types of human cancer and is used as therapeutic target. Although the association between HER2 expression and ovarian cancer has been widely studied, the results are still controversial Therefore, in the present study we will analyze the expression of both EGFR\& Her2neu in an OC tissue microarray (TMA) by immunohistochemistry, and results were be correlated to other clinicopathological parameters and prognosis.
Aim of the study:
General aim: To assess alterations of EGFR\& Her2neu expression in primary ovarian high grade serous carcinoma and its correlation with other clinicopathological parameters.
Specific objectives:
1. To measure the frequency of EGFR\& Her2neu immunohistochemical expression in ovarian high grade serous carcinoma.
2. To correlate between expression of EGFR\& Her2neu expression and other clinicopathological parameters of ovarian high grade serous carcinoma
3. To correlate between expression of EGFR\& Her2neu expression and prognosis of ovarian high grade serous carcinoma
Materials:
This cross-sectional study will be done on 54 specimens of ovarian primary high grade serous carcinoma cases who attended to Oncology Centre, Mansoura University, Mansoura, Egypt since 2012 to the end of 5 years follow up of the last patient The cases will be chosen randomly.
Methods:
1. All clinicopathological data of these cases will be collected such as Tumor size, LN metastases (N), metastasis (M), ascites, residual tumor, peritoneal deposits, recurrence, TNM staging \& (FIGO) staging system.
2. Prepare hematoxylin \& eosin slides to diagnose and assess other histopathological parameters such as histological type
3. Immunohistochemistry:
Sections 4μm thickness from newly formed tissue microarray blocks will be cut on coated slides then immunohistochemical staining using antibody against EGFR\& Her2neu will be done.
Statistical analysis:
SPSS software version 20 (SPSS Inc., Chicago, IL) will be used for analysis. For nominal variables, proportions and X2 tests will be applied, whereas for interval variables means, standard deviations (SD), and T test and ANOVA tests will be applied where appropriate. Kaplan-Meier method will be used for survival analysis. Chi-square test was used to estimate the relation between qualitative variables. Mann-Whitney test (non-parametric t test) was used for not normally distributed quantitative data, for comparison between two groups while, comparison between three groups was done using Kruskal-Wallis test (non-parametric ANOVA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Port Said University hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mayada saad
Lecturer of pathology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
pathology1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.